References
- Colatrella B. The Mectizan Donation Program: 20 years of successful collaboration - a retrospective. Ann Trop Med Parasitol 2008; 102:Suppl 1 7 - 11; http://dx.doi.org/10.1179/136485908X337418; PMID: 18718147
- Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al, Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23 - 33; http://dx.doi.org/10.1056/NEJMoa052664; PMID: 16394299
- Amador JJ, Vasquez J, Orozco M, Pedreira C, Malespin O, De Oliveira LH, et al. Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program. Int J Infect Dis 2010; 14:e592 - 5; http://dx.doi.org/10.1016/j.ijid.2009.08.014; PMID: 20022778
- Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006; 368:323 - 32; http://dx.doi.org/10.1016/S0140-6736(06)68815-6; PMID: 16860702
- Mast TC, Khawaja S, Espinoza F, Paniagua M, Del Carmen LP, Cardellino A, et al. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Ped. Infect Dis J 2011; 30:e209 - 15; http://dx.doi.org/10.1097/INF.0b013e31822a8527
- World Health Organization. Rotavirus vaccines. Wkly Epidemiol Rec 2007; 82:285 - 95; PMID: 17691162
- World Health Organization. Rotavirus vaccines:an update. Wkly Epidemiol Rec 2009; 84:533 - 40; PMID: 20034143
- Sack DA, Qadri F, Svennerholm A. Determinants of response to oral vaccines in developing countries. Ann Nestle 2008; 66:71 - 9; http://dx.doi.org/10.1159/000218195
- Center for Global Development. Making Markets for Vaccines- Ideas to Action. Available at: http://www.cgdev.org/doc/books/vaccine/MakingMarkets-complete.pdf., In: Ross-Larson B, Trott C, Walker T, Wilson E, eds. London: Grundy & Northedge, 2005.
- Amador JJ, Vicari A, Turcios-Ruiz RM, Melendez D AC, Malek M, Michel F, et al. Outbreak of rotavirus gastroenteritis with high mortality, Nicaragua, 2005. Rev Panam Salud Publica 2008; 23:277 - 84; http://dx.doi.org/10.1590/S1020-49892008000400008; PMID: 18505609
- PAHO. Country Health Profile: Nicaragua. Available at: http://www.paho.org/english/sha/prflnic.htm., 2002.
- WHO. WHO vaccine-preventable diseases: monitoring system - 2005 global summary. Available at: http://www.who.int/vaccines-documents., Geneva, Switzerland: WHO Document Production Services, 2005.
- Alliance GAVI. Available at: http://www.gavialliance.org/., 2011.
- William J. Clinton Foundation. William J. Clinton Foundation Annual Report 2008 Available at: http://www.clintonfoundation.org/about-the-clinton-foundation/annual-financial-reports., 2008.
- Schlesselman J, Stolley P. Research Strategies, Case-controls studies: design, conduct, analysis. New York: Oxford University Press, 1982: 7-26.
- Shapiro ED. Case-control studies of the effectiveness of vaccines: validity and assessment of potential bias. Pediatr Infect Dis J 2004; 23:127 - 31; http://dx.doi.org/10.1097/01.inf.0000109248.32907.1d; PMID: 14872178
- Martinez M. Merck y Minsa unen esfuerzos; Vacuna gratuita contra rotavirus Available at: http://impreso.elnuevodiario.com.ni/2006/09/23/contactoend/29630., Managua, Nicaragua: 2006.
- Merck. Merck's Plan to Accelerate Access to Vaccines in the Developing World Available at: http://www.merckresponsibility.com/priorities-and-performance/access-to-health/community-investment/public-and-private-partnerships/rotateq-access-partnership/home.html., 2009.
- Amador JJ. Nicaragua: Early experience with routine use of rotavirus vaccine. Presentation at: 8th International Rotavirus Symposium; Istanbul, Turkey; June 3-4, 2008: Available at: http://www.sabin.org/files/juan_jose_amador_ist.pdf., 2008.
- Mast C, Khawaja S, Zhu X, Espinoza F, Palacios L, Amador J, et al. Establishing rotavirus surveillance systems to evaluate the public health impact of rotavirus vaccine introduction in Nicaragua. Poster presented at International Rotavirus Symposium, Istanbul, Turkey, 2008.
- Mast TC. Demonstrating the public health impact of RotaTeq, The Merck & Co. and Nicaraguan Ministry of Health RotaTeq Partnership. Oral Presentation at 4th International Conference on Vaccines for Enteric Diseases, Lisbon, Portugal, 2007.
- Weston R, Hofman D. Merck: Accelerating New Vaccine Introduction in the Developing World; Available at: http://www.gartner.com/technology/research/reports/clinton-global-initiative.jsp, AMR Research, 2009.
- Bill & Melinda Gates Foundation. Living proof project: Tracing one rotavirus vaccine's winding path through Nicaragua. Available at http://www.gatesfoundation.org/livingproofproject/Pages/rotavirus-vaccine-path-to-nicargua.aspx
- 24. GAVI Alliance. Rotavirus vaccine support. Available at: http;//www.gavialliance.org/support/nvs/rotavirus/
- Munos MK, Walker CL, Black RE. The effect of rotavirus vaccine on diarrhoea mortality. Int J Epidemiol 2010; 39:Suppl 1 i56 - 62; http://dx.doi.org/10.1093/ije/dyq022; PMID: 20348127
- Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243 - 51; http://dx.doi.org/10.1001/jama.2009.756; PMID: 19491186
- Rwanda, Merck and QIAGEN launch Africa's first comprehensive cervical cancer prevention program incorporationg both HPV vaccination and HPV testing. 2011. Available at: http;//csrwire.commembers/12870-Merck-Co-Inc.
- Royal government of Bhutan, Merck and Australian cervical cancer foundation partner on vaccination program with Gardasil for girls and young women of Bhutan. 2010 Available at: http;//csrwire.commembers/12870-Merck-Co-Inc.